FDA: Celebs Rumors

+0

FDA may approve long-acting injectable PrEP by January

The Food and Drug Administration (FDA) may approve the first long-acting therapy for HIV pre-exposure prophylaxis (PrEP) within the next few months.On Tuesday, the pharmaceutical company ViiV Healthcare announced that the FDA has accepted and granted priority review for a new drug application (NDA) for cabotegravir, an injectable form of PrEP administered every two months. The FDA’s target approval date is Jan.
metroweekly.com

All news where FDA is mentioned

DMCA